AlphaMeld Corporation
Anita Ganjoo, Ph.D., is an accomplished professional in corporate communications with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Vice President of External Communications at Invea Therapeutics since November 2021 and Vice President of Corporate Communications at InveniAI since August 2018, Ganjoo has a strong background that includes a role in corporate communications at BioXcel Corporation from March 2014 to March 2017 and managerial responsibilities in media relations, education, and publishing at Genaissance Pharmaceuticals between September 1998 and August 2003. Ganjoo completed postgraduate studies at Lund University and the University of Reading, where a Ph.D. in Biotechnology was earned in 1995.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.